Organisation paid for research Program year 2021 Source: CMS Open Payments

Alliance Dermatology

Neither a doctor nor a teaching hospital

Research payments

$1,440,463

60 payments

Through program year 2021, Alliance Dermatology is reported as receiving $1,440,463 in research payments, across 60 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$206,607	27
2020	Research	$161,897	30
2019	Research	$1,071,959	3

Breakdown

Who paid Research payments · program years 2019–2021

Novartis Pharmaceuticals Corporation $1,071,959 3 payments
AbbVie, Inc. $368,505 57 payments

Studies the money was for Research payments · program years 2019–2021

A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis $1,059,951 1 payment
M16-045 $103,243 13 payments
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Subjects with Chronic Plaque Psoriasis $101,504 6 payments
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $63,594 12 payments
M15-999 $32,194 10 payments
A Phase 3b Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy $17,129 4 payments
P10-023 $15,910 4 payments
A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects with Moderate to Severe Plaque Psoriasis who have a Suboptimal Response to Secukinumab or Ixekizumab and are Switched to Risankizumab $13,630 1 payment
A Multicenter Double Blind Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long Term Efficacy Safety and Tolerability Up to 2 Years in Subjects With Moderate to Severe Chronic Plaque Type Psoriasis Co $11,934 1 payment
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA (Adalimumab) in Adult Patients with Chronic Plaque Psoriasis (PS) $10,750 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.